Background {#Sec1}
==========

A substantial number of surgical operations are conducted in the NHS each year, with most involving an incision \[[@CR1]\]. The edges of these incisions are often held together whilst healing occurs (primary closure); however, many surgical wounds break open or are left open to heal (healing by secondary intention). Surgical Wounds Healing by Secondary Intention (SWHSI) present a significant management challenge as they may remain open for many months and/or require multiple, additional treatments (e.g. prolonged hospitalisation, reoperation, infection management) \[[@CR2]\]. As a result, management of SWHSI presents a significant financial burden to the NHS and also impacts substantially on patients' quality of life.

There is much research evidence available to guide the management of SWHSI; however, as NICE reflected in their 2012 guidelines \[[@CR3]\], there is a need for robust, experimental evidence to assess the most clinical and cost-effective dressings and treatments for surgical site management. Negative Pressure Wound Therapy (NPWT) has become a widely used intervention for SWHSI, albeit more frequently within acute rather than community settings \[[@CR4]\]. NPWT devices apply negative pressure to a wound via a dressing which theoretically promotes wound healing by removing exudate and reducing infections \[[@CR5]\]. The device is generally only used for part of the SWHSI treatment pathway rather than to the point of healing.

A Cochrane Review in 2015 \[[@CR6]\] specifically investigated NPWT as a treatment for SWHSI; however, the review found only two trials eligible for inclusion. On the basis of this limited evidence and the fact that NPWT is widely used in the NHS to treat SWHSI, there is an urgent need to assess the effectiveness of this intervention in this specific patient population.

Previous trials of NPWT have struggled to recruit \[[@CR7], [@CR8]\] and so it would seem to be essential, before embarking on a full RCT, to assess the feasibility of conducting such research. Our study, therefore, seeks to ascertain the feasibility of conducting a full RCT in this area, specifically investigating the appropriate methods to use to collect meaningful and worthwhile data.

Methods {#Sec2}
=======

Design {#Sec3}
------

This study is a pilot RCT conducted in three centres to test the methods and feasibility of a full RCT of NPWT compared with usual care (no NPWT) for SWHSI. Informed consent will be obtained from each patient prior to randomisation into the study. Eligible patients will be individually randomised to one of two treatment arms: (1) NPWT or (2) usual care (no NPWT).

The key objectives of this trial are to determine the methods and feasibility of conducting a larger RCT in this area. Specifically, this pilot trial will assess:Recruitment rate including willingness of participants to be randomised and whether recruitment is influenced by wound location or other factors, e.g. associated surgical specialityClinician willingness and ability to recruit and randomise participantsTesting of inclusion and exclusion criteriaFitness for purpose of data collection methods including across and between care settingsAbility of sites and clinicians to supply NPWT to intervention participants in a timely fashion, irrespective of care setting, and to assess any training requirementsAbility of community staff to manage participants randomised to NPWTSuitability of method of outcome ascertainmentAdequacy of duration of follow-upRates of withdrawal from treatment, response rates to questionnaires, attrition from the trial, and likely rates of missing data for outcomesAssessment of feasibility of blinding outcome assessors to treatment allocationAcceptability of trial documentation to nurses collecting study data in addition to treating patientsThe primary outcome for this pilot trial will be time to complete wound healing (full wound epithelialisation). However, this pilot study is not looking to detect a treatment effect but to determine the ability to recruit to, and collect high-quality data in, a full RCT. Secondary outcomes and methods of data collection are summarised in Table [1](#Tab1){ref-type="table"}.Table 1Secondary outcome measuresSecondary outcomeMeasured by/usingNumber of patients screenedPre-Trial Screening Assessment FormNumber of patients eligible/ineligiblePre-Trial Screening Assessment FormAppropriateness of eligibility criteria and reasons for ineligibilityPre-Trial Screening Assessment FormProportion of eligible patients consenting to participate (and whether type of wound/surgical speciality impacts on this)Consent Form and Pre-Trial Screening Assessment FormTime between randomisation and treatment startPhase 1 Start of Treatment FormProportion of patients receiving randomised treatment within 48 hPhase 1 Start of Treatment FormDuration of Negative Pressure Wound Therapy (NPWT)Phase 1 Start of Treatment Form and End of Phase 1 Treatment FormFactors affecting timely delivery of randomised treatmentNon-immediate Use of NPWT FormWound dimensionsAssessment of Weekly Participant Events FormQuality and completeness of data collected for date of healingAssessment of Weekly Participant Events Form and Blinded Outcome Assessment FormPatient-reported health-related quality of lifeThe Short Form (12) Health Survey (SF-12) \[[@CR13]\]\
EuroQoL (EQ-5D) \[[@CR14]\]Cointerventions used and rate of treatment changeInvestigator Baseline Case Report Form (CRF), Assessment of Weekly Participant Events Form, Phase 1 Start of Treatment Form, Phase 1 End of Treatment FormSignificant events (e.g. rehospitalisation, infection, reoperation)Assessment of Weekly Participant Events FormAdverse eventsAdverse Event Form, Serious Adverse Event Form, Adverse Event/Serious Adverse Event Follow-up FormResponse ratesProportion of participant self-report measures returnedWithdrawal ratesChange of Status FormTreatment change including change from NPWT for intervention participants, reasons for changes and changes to NPWTSurgical Wounds Dressing Change Form, End of Phase 1 Treatment Form and Assessment of Weekly Participant Events FormResource useResource Use Questionnaire (3-month Participant CRF)Missing data ratesMissing responsesHealing ratesAssessment of Weekly Participant Events Form, Blinded Outcome Assessment FormBlinded outcome assessmentBlinded Outcome Assessment FormParticipant opinion on trial participationLikert Scales (3-month Participant CRF)Self-reported wound painWeekly text messaging\
Visual Analogue Scales (baseline, 2-week, 1-month and 3-month Participant CRFs)\
Brief Pain Inventory (BPI) (baseline, 2-week, 1-month and 3-month Participant CRFs) \[[@CR15]\]Wound progressPhotographs Wound tracings\
Depth measurements

Participants will be followed up every 1--2 weeks, depending on feasibility, for clinical outcome assessment. Participant-completed questionnaires will be completed at baseline, 2 weeks, 1 month, and 3 months post randomisation. Participants will be followed from randomisation to trial exit, which is deemed to be 3 months after randomisation, or loss to follow-up or death (if before this time). Participant flow through the trial and the schedule of study activities are displayed in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Participant flowchart and schedule of activity. Outlining participant flow through the study and outcome measurement completion time points

Inclusion and exclusion criteria {#Sec4}
--------------------------------

### Inclusion {#Sec5}

Our target population will be patients aged 18 years and over who are able to give full informed consent and who: are receiving care from either Hull and East Yorkshire Hospitals NHS Trust, Leeds Teaching Hospitals NHS Trust or Leeds Community Healthcare NHS Trust; have a SWHSI which could be reasonably treated with NPWT or wound dressings; have a SWHSI which is considered ready for NPWT (i.e. minimum 80 % viable tissue or thin layer of slough requiring no further debridement); and are receiving adequate nutrition (as assessed by the senior nurse responsible for nursing care).

### Exclusion {#Sec6}

We will exclude patients who: are unable to give informed consent; have limited life expectancy (e.g. are undergoing end-stage palliative care); have an active systemic infection; have already received NPWT on their current SWHSI, are currently receiving NPWT or received NPWT whilst in theatre for the surgery resulting in their SWHSI; have inadequate haemostasis or are at risk of bleeding; have chronic wounds such as pressure or foot ulcers which are nonsurgical in origin but which have been surgically debrided (we regard these patients as a distinctly different subgroup); are unwilling to have wound photographs taken; or are currently or have previously participated in a research study within the last 4 weeks.

Patients will also be excluded if they have any of the following wound characteristics present: unclear undermining in the wound cavity precluding use of NPWT; necrotic tissue or eschar; malignant tissue; exposed blood vessels and/or organs, anastomotic sites, and/or nerves (including cases where abdominal fascia is open); or located where a vacuum seal cannot be obtained (in the opinion of the treating clinician).

Recruitment {#Sec7}
-----------

Patients will be recruited from both acute and community settings within Hull and Leeds; however, we anticipate that most participants will be recruited from acute settings. The pilot trial will be preceded by promotion of the study with surgeons and nurses in both settings.

All patients who experience a SWHSI (at any point following surgery) will be screened for trial eligibility by their clinical care team. Potential participants will then be approached with further details of the study by surgical or nursing staff (clinical or research) during ward rounds, routine care or home visits, depending on patient circumstance.

Potential participants will be provided with a patient information sheet and will be given at least 24 h to consider their involvement in this research. Patients will then have the opportunity to discuss the study with the research team prior to completing the study consent form.

We aim to randomise 50 patients for this pilot trial over a 7-month period. As evidenced by Edwards et al. in 2002 \[[@CR9]\], nonconditional, monetary incentives are shown to double response rates to postal questionnaires; participants will, therefore, be sent a £5 unconditional cash token with their final questionnaire (at 3 months post randomisation). Participants who consent to receiving weekly text messages, and provide a mobile telephone number to facilitate this, will also be reimbursed £5 to cover any costs incurred in responding to weekly pain assessment text messages.

Randomisation {#Sec8}
-------------

Patients will be randomised into one of two arms: (1) NPWT or (2) usual care (no NPWT) on a 1:1 basis. To remove the potential for selection bias, allocations will be concealed through use of a central randomisation service implemented by an independent member of staff at the York Trials Unit, University of York. Study sites will contact a remote telephone service to provide details of the participant and to receive details of the treatment allocation. Randomisation will be conducted using a pregenerated sequence of random permuted blocks with stratification by wound area (\<28 cm^2^, ≥28 cm^2^).

Due to the nature of the intervention it is not possible to blind participants or health care professionals to trial treatment. Feasibility of blinded outcome assessment of healing will, however, be assessed as part of this trial. Assessors blind to trial treatment allocation will be provided with copies of wound photographs and will be asked to confirm whether (1) they deem the wound to be healed (full wound epithelialisation), and (2) they believe they know the allocated treatment allocation.

Sample size {#Sec9}
-----------

As this is a pilot trial, and the primary objective is to determine measures of feasibility and acceptability rather than to detect a treatment effect, a formal sample size calculation has not been conducted. We will, however, aim to randomise approximately 50 patients as a means to assess recruitment, randomisation, and retention of participants.

Interventions {#Sec10}
-------------

### Experimental group: Negative Pressure Wound Therapy {#Sec11}

There are several NPWT systems available within the NHS; however, for the purposes of this trial we originally permitted the use of the following CE-marked products currently used in acute and community settings in Hull and Leeds: (1) V.A.C.® (KCI), and (2) Renasys® (Smith and Nephew). A further device (PICO® -- Smith and Nephew) has subsequently been added as a trial device in a recent protocol amendment.

NPWT treatments consist of a vacuum pump into which a disposable plastic canister is placed to enable wound exudate to be collected. The canister is attached to pressure resistant tubing to create an airtight seal. The wound to be treated is filled with a suitable dressing (foam or gauze) along with a nonadherent layer, if required, to protect blood vessels or organs and/or to prevent dressing adherence.

In this trial, the choice of machine and duration of NPWT will be decided by the treating health professional in conjunction with the participant and nurse. Pressure cycles and dressing change frequency will be completed as per standard practice and recorded. The only stipulation with regards NPWT use is that this must be clinically appropriate. When not being treated with NPWT, participants in this arm of the trial will be treated as per usual care.

### Comparator group: Usual Care (no NPWT) {#Sec12}

The control group participants will receive usual care. This is likely to be wound dressings which will be changed every 1--3 days, or sometimes less frequently, as determined by the treating surgeon or nurse in line with standard practice. The trial protocol does not stipulate the type of dressings which should be used as part of usual care as there is no evidence to suggest that any one dressing is more clinically or cost-effective than another. Control dressings are, therefore, selected by the clinician on the basis of the dressing most appropriate for the patient. The types of primary and secondary dressings used, and the frequency of dressing change, will be recorded throughout the trial.

Statistical analysis {#Sec13}
--------------------

A full statistical analysis plan for primary and secondary analyses will be generated prior to completion of recruitment for this trial. The Trial Management Group and the Data Monitoring and Ethics Committee (DMEC) will review this prior to commencement of outcome analysis. During the trial regular reports will be prepared for the DMEC with regards data quality and safety.

The analyses will be conducted following the principles of intention-to-treat. All outcomes will be summarised using descriptive statistics overall and by trial group.

The primary clinical outcome of time to healing will be presented using Kaplan-Meier curves for interest only, recognising that the study is not powered to detect clinically important treatment effects. This analysis will be conducted using blinded outcome assessment dates of healing if possible. A Cox proportional hazards regression analysis will be conducted, subject to sufficient data, to investigate the inclusion of additional covariates shown to be important in an earlier SWHSI cohort (e.g. contamination level of surgery, wound infection), along with the stratification factor (baseline wound size) used in the randomisation for this trial. The impact of SWHSI history, location of SWHSI on the body and infection at any time during follow-up (as a time dependent covariate) will also be explored.

Cost-effectiveness will be explored by calculating a mean total cost per trial arm using resource use and relevant unit costs for each participant. Should sufficient data be available, EuroQoL 5 dimensions (EQ-5D) questionnaire data will be used to calculate a mean quality-adjusted life year (QALY) for each trial arm.

Patient and Public Involvement {#Sec14}
------------------------------

Patient and Public Involvement (PPI) comes from a patient user group comprising 10 members who have contributed to the design and conduct of the study. This has included input on the outcomes collected, study documentation design and wording, and will include input into planned dissemination of research findings. The group members are patients who have participated in an earlier SWHSI cohort study. PPI members will be appropriately reimbursed for their participation in line with INVOLVE guidelines \[[@CR10]\].

The Trial Steering and Data Monitoring and Ethics Committees {#Sec15}
------------------------------------------------------------

As this is a pilot trial, the study will be monitored closely by an in-house Trial Management Team who will meet on a monthly basis. A Trial Steering Committee will not be convened for this trial.

A Data Monitoring and Ethics Committee (DMEC) will be formed to routinely review data, participant safety, and protocol compliance. The committee will consist of independent members: a statistician; two clinicians; and a PPI representative who will meet, at minimum, once prior to study commencement and once during the study duration.

Forecast execution dates {#Sec16}
------------------------

The set-up of the trial commenced on 8 October 2015, following Research Ethics Committee (REC) approval, and was completed in March 2016. Recruitment of participants commenced on 20 November 2015 and will be completed on 30 June 2016. Follow-up for the trial commenced in December 2015 and will continue until 30 September 2016. Data analysis will commence in October 2016. The final report associated with this programme grant will be submitted in February 2017.

Protocol changes {#Sec17}
----------------

Protocol amendments made since the start of this trial are detailed in Table [2](#Tab2){ref-type="table"}.Table 2Protocol amendments made following commencement of the trialAspect of the trialAmendment madeWound measurementsDepth measurement will be conducted by swab or probeAdverse eventsSerious, related, and ongoing events will be followed up for 1 month after trial exitClarification of definitions of unplanned and prolonged hospitalisationIntervention/controlFrequency of surgical wound dressing changes will be recordedAddition of further trial device (PICO® -- Smith and Nephew)Study processesPatients who have their reference wound amputated will continue to be followed up for participant-reported measuresPatient and Public Involvement (PPI)Patients in the SWHSI trial will be approached at the end of their trial involvement, with regards involvement in a PPI group.*SWHSI* surgical Wounds Healing by Secondary Intention

The study protocol has been written in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement \[[@CR11]\] and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist \[[@CR12]\], as provided in Additional file [1](#MOESM1){ref-type="media"}.

Discussion {#Sec18}
==========

The proposed trial will explore methods for, and feasibility of, completing a full RCT to assess clinical and cost-effectiveness of NPWT for treatment of SWHSI compared with usual care. As would be expected with a feasibility trial, some barriers have been identified which may impact on recruitment and time to completion of the pilot or larger RCT in the future.

Engagement of sites {#Sec19}
-------------------

During the set-up of the trial, the research sites have worked closely with their clinical colleagues to promote the trial. Promotion included contact with specialist teams, letters to surgeons, and posters advertising the study to clinical staff. Despite these efforts engagement of surgical and clinical colleagues has been mixed which has resulted in slower than anticipated recruitment. Continued efforts at a local level have helped to alleviate the lack of engagement as the trial has progressed resulting in an improvement in recruitment rate. Substantial work during set-up, and use of additional strategies to engage clinical staff should, however, be explored ahead of commencement of a larger RCT.

Governance issues {#Sec20}
-----------------

Governance delays arose in one NHS trust due to circumstances outside of the trial's control. This subsequently delayed opening of two colocated study sites, which impacted upon recruitment rate in the early stages of the trial. Despite this reduced recruitment in the early stages of the trial, recruitment has subsequently increased in all trusts, with the study meeting the target monthly recruitment in the following 4 months.

Trial status {#Sec21}
============

At the time of submission the trial is open to recruitment.

Additional file {#Sec22}
===============

Additional file 1:SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 119 kb)
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QALY

:   Quality-adjusted life year

RCT

:   Randomised controlled trial

SF-12

:   Short Form 12

SWHSI

:   Surgical Wounds Healing by Secondary Intention

We would like to acknowledge the support of everyone involved in the trial including the trust sites, research nurses, and the patient user group.

Funding {#FPar1}
=======

This project was funded by the NIHR Programme Grants for Applied Research Programme (project number RP-PG-0609-10171). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, CCF, NETSCC, the Programme Grants for Applied Research Programme or the Department of Health.

Availability of data and materials {#FPar2}
==================================

Not applicable.

Authors' contributions {#FPar3}
======================

IC, NC, JD, DT, MS, and AO conceived the idea for the study, obtained funding for the study and contributed to the trial design, intervention and outcome measures. HB conceived the statistical analyses and sample size. CF contributed to the statistical analysis and sample size sections of the manuscript. CA, EC, AF, KL, EMcG, PSG, NS, and SD contributed to the trial design, intervention and outcome measures. CA and IC drafted the manuscript. All authors reviewed the draft manuscript and have read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

Ethical approval for this trial has been granted by the Leeds East Research Ethics Committee -- reference 15-YH-0307. Participants are required to provide informed consent prior to participation.
